Exagen (XGN)
Develops AVISE tests for diagnosis and monitoring of autoimmune disease.
Something off on this page? Send us feedback.
Develops and commercializes AVISE-branded diagnostic tests for complex rheumatic and autoimmune conditions. AVISE CTD is the flagship product, using CB-CAPs technology to support differential diagnosis, prognosis, and disease monitoring.
Develops and commercializes AVISE-branded diagnostic tests for clinicians managing complex rheumatic and autoimmune conditions. Its flagship AVISE CTD test supports differential diagnosis of those conditions; the portfolio also addresses prognosis and ongoing disease monitoring.
Built around CB-CAPs technology, the testing franchise is intended to help clinicians reach timely assessments and guide management of chronic autoimmune disease. AVISE CTD has been the commercial anchor since its 2012 launch, and recent product updates added rheumatoid-arthritis offerings. The business is headquartered in Vista, California, and its core activity remains the design and commercialization of autoimmune diagnostic tests.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Jun 24, 2026 | Roth Capital | Initiate | Rating: —Target: — | Target: $8 |
| May 12, 2026 | BTIG | Reiterate | Rating: —Target: $9 | Target: $8 |
| Apr 20, 2026 | Canaccord Genuity | Reiterate | Rating: —Target: $15 | Target: $8 |
| Mar 11, 2026 | UBS | Target | Target: — | Target: $10 |
| Mar 10, 2026 | BTIG | Reiterate | Rating: —Target: $10 | Target: $9 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $24.6M · Total debt $25.5M · Total assets $51.9M · Shareholders' equity $12.2M
- Revenue
- $19.9M
- Operating income
- −$1.7M
- Net income
- −$3.2M
No dividends on record.
| Institutions | 32.81% | 7.95M shares | |
|---|---|---|---|
| 57 holders · as of Jun 30, 2026 | |||
| Insiders | 14.77% | 3.58M shares | |
| 3 holders · as of Sep 2, 2026 | |||
| Strategic holders | 5.65% | 1.37M shares | |
| 1 holder · as of Feb 11, 2026 | |||
| Other | 46.77% | 11.33M shares | |
| remainder | |||
24.23M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Chernett JoreyInsider | 9.96% | 2.41M | filed May 20, 2026 |
NMSIC Co-Investment Fund, L.P.1Strategic10 percent owner | 5.65% | 1.37M | filed Feb 11, 2026 |
Parian Ultreia LPInstitution | 5.33% | 1.29M | filed May 27, 2026 |
John AballiInsiderdirector, officer: President and CEO | 3.47% | 839,834 | filed Mar 16, 2026 |
Wexford Capital LPInstitution | 3.27% | 792,855 | as of Jun 30, 2026 |
- NMSIC Co-Investment Fund, L.P.'s own ownership statement (13G, Feb 11, 2026) reports fewer shares than the transaction reports; the statement is used.
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 1, 2026 | Jeffrey G. Black | officer: Chief Financial Officer | −20,614 | $7.22 |
| Mar 3, 2026 | John Aballi | director, officer: President and CEO | −15,698 | $3.62 |
| Feb 24, 2026 | Jeffrey G. Black | officer: Chief Financial Officer | −1,584 | $3.61 |
| Feb 24, 2026 | John Aballi | director, officer: President and CEO | −11,430 | $3.61 |
| Oct 16, 2025 | John Aballi | director, officer: President and CEO | −31,787 | $11.82 |
- Quest Diagnostics
Broad autoimmune panels for rheumatology practices and laboratories
- Labcorp
Rheumatology test portfolios for autoimmune and connective-tissue disease
- Thermo Fisher Scientific
Automated autoimmune assays for CTD and rheumatoid arthritis laboratories
- Revvity
EUROIMMUN laboratory systems and assays for specialty autoimmune testing
CompareAfter hours
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Exagen | $8.74 | −0.23% | $208.3M | — | — | 2.9 | +15.9% |
| Quest Diagnostics | $234.76 | −0.04% | $27.03B | 26.0 | 20.5 | 2.3 | +10.2% |
| Labcorp | $311.54 | +0.05% | $26.32B | 26.6 | 16.4 | 1.8 | +5.8% |
| Thermo Fisher Scientific | $658.52 | −0.03% | $244.81B | 35.4 | 25.1 | 5.3 | +10.5% |
| Revvity | $143.31 | 0.00% | $16.02B | 68.4 | 25.5 | 5.5 | −1.3% |
| Median | 31.0 | 22.8 | 3.8 | +8.0% |